Abstract: Processes comprising: providing a reactive distillation column having an upper region, a middle region and a lower region; feeding ethylene glycol and an aqueous formaldehyde solution into the reactive distillation column in the middle region of the reactive distillation column; reacting the ethylene glycol and the aqueous formaldehyde solution in the reactive distillation column in the presence of a catalyst to form dioxolane; removing a product stream comprising dioxolane in an amount of at least 75% by weight from the upper region of the reactive distillation column; and removing a bottom stream comprising one or more components having boiling points higher than dioxolane from the lower region of the reactive distillation column.

Abstract: A compound which satisfies requirements for the annealing property and the lubricating property simultaneously and a process for producing the compound are provided. The compound is an alkylacetal compound represented by the following general formula (1) or (2). In the general formulae, R1 and R2 represent hydrocarbon groups, R3 to R8 represent hydrogen atom or hydrocarbon groups, i and j represent integers satisfying the relation that the sum of the integers is 8 to 98, and k represents 0 or 1.

Abstract: An acetal of formula I: is described in which the radicals R1 to R6 independently of one another are eac hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, n=0 or 1, and there is a single bond or double bond at the location of a broken line between two C atoms, any double bond present in the chain linking the aliphatic ring to the acetal group having the E or Z configuration, with the proviso that the number of double bonds incorporating a C atom of the aliphatic ring is 0 or 1, and the number of double bonds not incorporating a C atom of the aliphatic ring is 0 or 1.

Abstract: A process for the preparation of a fuel oil (diesel fuel or heating oil) composition which is a mixture of an alkanol tranesterified fatty acid ester triglyceride and an acetal of glycerol is described. The process preferably provides a prestep of the formation of at least some of the alkanol transesterified triglyceride containing the glycerol for use in the formation of the acetal of glycerol. The composition can also be formed from a reaction of 1,1-dimethoxy- or 1,1-diethoxyethane and glycerol to form the acetal in the alkanol transesterified triglyceride.

Abstract: The present invention relates to a cyclic ketone peroxide formulation comprising one or more crystallizing cyclic ketone peroxides, one or more co-crystallizing compounds which solidify in said cyclic ketone peroxide formulation at a temperature above the crystallization temperature of the crystallizing cyclic ketone peroxide, and, optionally, one or more conventional phlegmatizers (diluents). These formulations show improved safety and storage stability compared to conventional cyclic ketone peroxide formulations. The invention also pertains to the use of these formulations in (co)polymerization and (co)polymer modification processes.

Abstract: The present invention relates to hexahydroindan acetal and ketal compounds and their use as fragrance chemicals suitable for incorporation in fine fragrances, cosmetics, toiletries and related applications.

Abstract: Compounds of Formula I, wherein R1–R8 are defined herein are provided, together with pharmaceutically acceptable salts, hydrates, metabolites, and/or prodrugs thereof. Uses of these compounds for inhibiting beta amyloid production and for the prevention and treatment of Alzheimer's Disease and Down's syndrome are described.

Abstract: The present invention provides piperine and analogues or derivatives thereof for the treatment of skin conditions treatable by stimulation of melanocyte proliferation, such as vitiligo, and also for treating skin cancer. The piperine and analogues or derivatives thereof may also be used to cosmetically promote or enhance the natural coloration of the skin.

Abstract: An infrared dye, characterized in that the dye comprises of Formulae 1 to 5

Abstract: A process for preparing intermediate compound (VII), compound (VIII) and compound (XIV) which will be raw materials for the synthesis of a synthetic antibactrial compound, via compound (I) or compound (X) and then, compound (II), the compounds each being shown below; and novel compounds useful for the preparation.

Abstract: The invention relates to chiral compounds of formula (I) wherein Y1, Y2, Y3, Y4, X1, X2, X3 and X4 have the meaning given in claim 1, to liquid crystalline mixtures comprising at least one chiral compound of formula (I), to chiral linear or crosslinked liquid crystalline polymers obtainable by polymerizing a polymerizable mixture comprising at least one chiral compound of formula (I), to the use of chiral compounds of formula (I) and mixtures and polymers obtained thereof in liquid crystal displays, active and passive optical elements, adhesives, synthetic resins with anisotropic mechanical properties, cosmetic and pharmaceutical compositions, diagnostics, liquid crystal pigments, for decorative and security applications, nonlinear optics, optical information storage or as chiral dopants, and to a liquid crystal display comprising a mixture comprising at least one chiral compound of formula (I)

Abstract: The invention concerns a novel compounds of formula (I), wherein the dotted line bond is present or not, and wherein R1 represents: when the dotted line bond is present —CHCH3OH or —CHCH3OCOR or —CHCH3XCH2CHOHR? or —CHCH3OCHR?CH2OH or formula (II) when the dotted line bond is absent —CHCH3OH or —CHCH3OCOR or —COCH3 or formula (II) or —CHCH3XCH2CHOHR? or —CH2CH2XCH2CHOHR? or —CHCH3OCHR?CH2OH or —CHCHCOR? or —CH2CH2CHR?OH or —CH2CH2CHR?OCOR or CHCHCHOHR? or —CHCHCHR?OCOR, wherein R represents H, Me, Et, Pr, isoPr, But, isoBut, CH3CH2)4, (CH3)2CHCH2, CH2CH, (CH3)2CCH, and R? represents H, Me or Et, and X represents O, N or S, and their preparation method. Because of their fragrance, said compounds are highly interesting for the perfume industry, for cosmetic and care products.

Abstract: The invention provides dicarboxylic acid-substituted heteroaryl derivatives of the formula G1-(C(R1)R2)n-Q1-B-Q2-(C(R3)R4)m-G2??I or a pharmaceutically acceptable salt thereof, wherein G1, G2, R1, R2, R3, R4, n, m, Q1, Q2, and B are as defined in the specification. The invention compounds are inhibitors of matrix metalloproteinase enzymes, including MMP-13. This invention also provides pharmaceutical compositions and methods of treating diseases mediated by MMP-13, including arthritis, asthma, heart disease, atherosclerosis, and osteoporosis, or a pharmaceutically acceptable salt thereof.

Abstract: Compounds of the general formula (I) are described: wherein each of R1, R2, R3, R4, R5 and R6 independently represents a substituent selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, and isopropyl; an wherein x represents either 0 or 1. The compounds are useful as fragrances and as added components in fragrance blends. Methods of improving the harmony, emanation, naturalness an staying power of other fragrance ingredients by the addition of such compounds are also described.

Abstract: The invention relates to: 4-methylene-1,3-dioxolanes of the general formula (I) wherein R1 denotes hydrogen, C5-C6-cycloalkyl or C1-C4-alkyl; m and n, which may be the same or different, denote 0 or 1, whereby m?n, o denotes 2, 3 or 4 depending on the valency of the group X; and X denotes a C—C single bond, straight-chain or branched C1-C18-alkylene, C5-C6-cycloalkylene, C8-C18-arylalkylene, —CH2(OCH2CH2)pOCH2—, —CH2(OCH(CH3)CH2)pOCH2—, wherein p is an integer from 0 to 100; a process for their production; and intermediate products used. Moreover, compositions capable of emission-free, photocationic cross-linking, which comprise 4-methylene-1,3-dioxolanes of the general formula (I) and their use for the production of solvent-resistant and transparent films.

Abstract: A unique class of chiral additive materials is disclosed for use in cholesteric displays that possess a helical twist power substantially independent of temperature. The additives have a solubility and a helical twist power large enough to be used as a single chiral component with little dilution of the physical properties of the nematic liquid crystal host mixture. The chiral additives may be used in combination with non-chiral additives to provide a helical twisting power substantially independent of temperature suitable for cholesteric displays.

Abstract: The present invention provides substituted 3,3-diphenyl indanone, indane and indole compounds, as well as analogues thereof, which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.

Abstract: The present invention relates to a process for preparing acetals of &agr;,&bgr;-dicarbonyl compounds of the general formula

Abstract: The present invention relates to a cyclic ketone peroxide formulation comprising one or more crystallizing cyclic ketone peroxides, one or more co-crystallizing compounds which solidify in said cyclic ketone peroxide formulation at a temperature above the crystallization temperature of the crystallizing cyclic ketone peroxide, and, optionally, one or more conventional phlegmatizers (diluents). These formulations show improved safety and storage stability compared to conventional cyclic ketone peroxide formulations. The invention also pertains to the use of these formulations in (co)polymerization and (co)polymer modification processes.

Abstract: A process for the preparation heterocyclic indene analogs, especially with the preparation of 4-hydroxycarbazole or N-protected 4-hydroxycarbazole, involves cyclocarbonylation followed by saponification. This process avoids high temperatures and high catalyst loadings.

Abstract: Embodiments of the invention relate to C2-substituted indan-1-ones and to their physiologically acceptable salts and physiologically functional derivatives. Compounds of embodiments of the invention include compounds of formula I in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for use as anorectics.

Abstract: This invention relates to the reversible protection of hydroxy-silane functional groups by acid cleavable protecting groups. The development of reversible protecting groups greatly enhances the current utility of silanes while introducing further novel applications. For instance, reversibly protected silanes are of particular value in applications where room temperature cure and/or adhesion is of value, such as coatings, high resolution imaging, caulks, adhesives, sealents, gaskets, and silicones. Reversibly protected silanes can also be beneficially used in reticulating agents, and in sizing agents, tires, and release coatings. The incorporation of reversibly protected silanes into coating resins is of particular value. The reversibly protected silane can be incorporated into the coating resin by polymerizing a monomer containing the reversibly protected silane into the resin or by post-addition into the coating formulation.

Abstract: A new inhibitor of microtubule assembly (IC50 0.59 &mgr;M); with antineoplastic properties, denominated “dioxostatin”, has been synthesized and its effectiveness against human cancer and murine P388 lymphocytic leukemia cell lines demonstrated. Dioxostatin hs the following structure (I).

Abstract: The present invention provides novel processes for preparing a fluorinated acyl fluoride and a fluorinated vinyl ether.

Abstract: Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a muscarinic receptor antagonist or an allosteric modulator provided that at least one of said ligand is a muscarinic receptor antagonist. The multibinding compounds of this invention are useful in the treatment and prevention of diseases such as chronic obstructive pulmonary disease, chronic bronchitis, irritable bowel syndrome, urinary incontinence, and the like.

Abstract: A method for producing unsaturated cyclic ethers of general formula (I) wherein Z represents (CHR4)q— or (CHR4)q—O—, q 0, 1, 2 or 3 and R1, R2, R3, R4 represent hydrogen or C1-C4-alkyl, by reacting dioles of general formula (II), wherein Z, R1, R2 and R3 have the above-mentioned meanings, in a liquid phase at temperatures of 150-300° C. in the presence of a support catalyst which is not activated prior to use by reduction and which contains cobalt and is doped with sulphur, containing cobalt, and an earth metal which is deposited by sol impregnation and is selected from the group containing platinum, palladium, rhodium, iridium, ruthenium, osmium, rhenium or mixtures thereof, on an inert support, characterized in that water is added.

Abstract: A process for the separation of a polyol or multiple polyols in admixture with other organic compounds, usually those produced with the polyol, is described. The process uses a distillation in a column (11) of a cyclic acetal from an aqueous solution which acetal is formed in a reaction mixture of the polyol and an aldehyde or ketone. The polyols, such as ethylene glycol and propylene glycol, are staple articles of commerce with many uses.

Abstract: The invention relates to a process for the preparation of compounds containing at least one —CF2—O— bridge in the molecule, in which

Abstract: The invention describes novel substituted aryl compounds that are cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or, optionally, at least one therapeutic agent, such as, steroids, nonsterodal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B4 (LTB4) receptor antagonists, leukotriene A4 (LTA4) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors, H2 antagonists, antineoplastic agents, antiplatelet agents, thrombin inhibitors, thromboxane inhibitors, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pyl

Abstract: The present invention provides piperine and analogues or derivatives thereof for the treatment of skin conditions treatable by stimulation of melanocyte proliferation, such as vitiligo, and also for treating skin cancer. The piperine and analogues or derivatives thereof may also be used to cosmetically promote or enhance the natural coloration of the skin.

Abstract: The present invention provides a novel compound having an excellent acetylcholinesterase inhibitory effect. That is, it provides a 4-substituted piperidine compound fluoride represented by the following formula, a pharmaceutically acceptable salt thereof or hydrates thereof (provided that 1-benzyl-4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine, a pharmaceutically acceptable salt thereof and hydrates thereof are excluded). wherein R1 and R2 represent substituents.

Abstract: Compounds of Formula I, 1

Abstract: In producing a cyclic formal by feeding an alkylene glycol and a formaldehyde derivative as starting materials to a reaction vessel and reacting them in the presence of a catalyst, the value of amount of alkylene glycol (mole)/amount of formaldehyde derivative in terms of formaldehyde (mole) is kept at 0.02-0.95 at the time of feeding of the starting materials and at 1.05-50 at the time of reaction of the starting materials. According to this process, the amount of by-product impurities at the reaction step can be reduced, and an additional purification step of the cyclic formal is not needed or can be easily performed.

Abstract: The invention provides a process for producing a fluorine-containing compound from an inexpensive material.

Abstract: aP2 inhibiting compounds are provided having the formula 1

Abstract: A process for the separation of a polyol or multiple polyols in admixture with other organic compounds, usually those produced with the polyol, is described. The process uses a distillation in a column (11) of a cyclic acetal from an aqueous solution which acetal is formed in a reaction mixture of the polyol and an aldehyde or ketone. The polyols, such as ethylene glycol and propylene glycol, are staple articles of commerce with many uses.

Abstract: The invention relates to a process for preparing 2,7-dimethyl-2,4,6-octatrienal monoacetals of the general formula I which comprises a) condensing an ester phosphonium salt of the general formula II or an ester phosphonate of the general formula III with an aldehyde of the formula IV in a Wittig or Wittig-Horner reaction to give an acetal ester of the general formula V b) reducing the ester of the formula V to give an acetal alcohol of the general formula VI and c) oxidizing the alcohol to 2,7-dimethyl-2,4,6-octatrienal monoacetals of the general formula I, where the substituents have the meaning defined in the description.

Abstract: The present invention relates to prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient. This invention also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs and pharmaceutical compositions of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance. This invention also relates to methods of treating mammals with these prodrugs and pharmaceutical compositions.

Abstract: Artificial tanning in human skin is induced by 2,2-dihydroxymethyl-1,3-dioxolanes in the presence of water. The 2,2-dihydroxymethyl-1,3-dioxolane is formed by the reaction of 1,3-dihydroxyacetone with a cosmetically acceptable 1,2-diol under anhydrous conditions. The resultant dioloxane is incorporated directly into a cosmetic composition, which is subsequently applied to the skin. The self-tanning reaction rates of 2,2-dihydroxymethyl-4-methyl-1,3-dioxolane and 2,2-dihydroxymethyl-4-ethyl-1,3-dioxolane are approximately equal to 1,3-dihydroxyacetone in water once applied to moistened human skin.

Abstract: In producing a cyclic formal by feeding an alkylene glycol and a formaldehyde derivative as starting materials to a reaction vessel and reacting them in the presence of a catalyst, the value of amount of alkylene glycol (mole)/amount of formaldehyde derivative in terms of formaldehyde (mole) is kept at 0.02-0.95 at the time of feeding of the starting materials and at 1.05-50 at the time of reaction of the starting materials. According to this process, the amount of by-product impurities at the reaction step can be reduced, and an additional purification step of the cyclic formal is not needed or can be easily performed.

Abstract: The novel compositions and methods of the subject invention can be used in antifugal applications. The antifugal agents of the subject invention can be used in the treatment of an animal or human having a fugal infection. In a further embodiment the compounds can be used to treat plant fugal infections, disinfect surfaces, and prevent spoilage of organic compositions such as food and cosmetics.

Abstract: Cyclic acetal compounds of formula (1) wherein k=0 or 1 and n is an integer of 0 to 6 are novel. Using the cyclic acetal compounds as a monomer, polymers are obtained. A resist composition comprising the polymer as a base resin is sensitive to high-energy radiation and has excellent sensitivity, resolution, and etching resistance.

Abstract: Optical data carrier comprising a preferably transparent substrate which may, if desired, have previously been coated with one or more reflection layers and to whose surface a light-writeable information layer, if desired one or more reflection layers and if desired a protective layer or a further substrate or a covering layer have been applied, which can be written on or read by means of blue, red or infrared light, preferably laser light, where the information layer comprises a light-absorbent compound and, if desired, a binder, characterized in that at least one cationic aminoheterocyclic dye is used as light-absorbent compound.

Abstract: Photoresist monomers of following Formula 1, photoresist polymers thereof, and photoresist compositions containing the same. The photoresist composition has excellent etching resistance, heat resistance and adhesiveness to a wafer, and is developable in aqueous tetramethylammonium hydroxide (TMAH) solution. In addition, the photoresist composition has low light absorbance at 157 nm wavelength, and thus is suitable for a photolithography process using ultraviolet light sources such as VUV (157 nm) in fabricating a minute circuit for a high integration semiconductor device.

Abstract: Diels-Alder adducts of dienophiles such as epoxybutene with dienes such as cyclopentadiene and cyclohexadiene are produced by carrying out the Diels-Alder reaction thereof at an elevated pressure. Addional dienophiles disclosed include 2,5-dihydrofuran and derivatives thereof; Additional dienes include isoprene and butadiene. Compounds produced from such reactions are also disclosed.

Abstract: The present invention relates to a cross-linker for use in a photoresist which is suitable for a photolithography process using KrF (248 ru), ArF (193 nm), E-beam, ion beam or EUV light source. According to the present invention, preferred cross-linkers comprise a copolymer having repeating units derived from: (i) a compound represented by following Chemical Formula 1 and/or (ii) one or more compound(s) selected from the group consisting of acrylic acid, methacrylic acid and maleic anhydride.

Abstract: This invention provides a process for the preparation of a racemic mixture of dysidiolide a method for inhibiting growth of cancerous cells comprising contracting an amount of the racemic mixture of dysidiolide effective to inhibit the growth of said cells. Further provided is a method for treating cancer in a subject which comprises administering to the subject a therapeutically effective amount of the racemic mixture of dysidiolide.

Abstract: This invention relates to a monomer shown by the general formula [1] (wherein X′ is a cyclic hydrocarbon residue containing polymerizable double bond(s), which may have a substituent, Z is a spacer or a direct bond and R is a substituted alkyl or alkenyl group having one or two protected hydroxyl groups as substituent) and a polymer containing a segment derived from the above monomer. The said polymer is useful for a resist composition, etc. utilized in the production of semiconductor elements, etc. and the said monomer is useful as a starting material for the polymer, and a resist composition using the said polymer can remarkably advantageously be used as a resist material for ArF excimer laser beams which has been considered to be a valuable technology for exposure belonging to the coming generation.

Abstract: Aromatic aldehyde compounds of formula (4) and (6) are disclosed, wherein Y is a methylene group with various substitutions and R represents various substituents.

Abstract: This invention provides an improved process for cis-1-{2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl}pyrrolidine which is an intermediate for the preparation of (−)cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol which is useful for the treatment of osteoporosis.